Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders
AssigneeGenentech, Inc.
InventorsSoumitra Roy, Gordon A. Vehar
Life of this patent
Estimating the term…
Abstract
A tissue factor protein mutant capable of neutralizing the ability of endogenous tissue factor to induce coagulation is provided. A representative tissue factor mutant designated K165A, K166A TF is useful in a method for inhibiting thrombin-induced platelet aggregation in a mammal, either separately or in combination with a thrombolytic agent, an anticoagulant, or a GPII.sub.b III.sub.a inhibitor.
Claims13
A tissue factor protein mutant capable of inhibiting the ability of endogenous tissue factor to induce coagulation, wherein either or both the positively charged amino acid residues 165 and 166 are substituted with an .alpha.-amino acid other than one bearing a substantially positively charged side chain at physiological pH.
Dependencies are inferred from the claim text.